Steven S. Rosenfeld, Md, PhD
Steven S. Rosenfeld, M.D., Ph.D., is a neurologist whose research focuses on identifying novel and effective therapeutics to treat glioblastoma, the most common and lethal of primary brain tumors. In particular, Dr. Rosenfeld's laboratory team is developing treatment approaches that target molecular motors — intracellular enzymes that move cells, driving tumor cell invasion, and chromosomes, driving tumor cell proliferation. Dr. Rosenfeld's team has shown that targeting molecular motors with genetic and pharmacologic means in animal models of glioblastoma is well tolerated and effective in prolonging survival, key first steps in getting new therapies into the clinic. Dr. Rosenfeld is also examining how to improve on this therapeutic approach by combining it with established anticancer drugs and radiation therapy.
Thursday Day 2</br>24th October 2024
Friday Day 3</br>25th October 2024